KOPRAN
|
KOPRAN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| CEPS(Rs) | 11.21 | 13.24 | 8.29 | 14.96 | 16.60 |
| DPS(Rs) | 3.00 | 3.00 | 3.00 | 3.00 | 1.50 |
| Book NAV/Share(Rs) | 107.02 | 101.68 | 91.11 | 88.40 | 56.65 |
| Tax Rate(%) | 25.79 | 24.56 | 24.49 | 25.37 | 26.07 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.58 | 12.10 | 9.28 | 18.00 | 16.29 |
| EBIT Margin(%) | 9.73 | 12.39 | 7.55 | 17.93 | 17.87 |
| Pre Tax Margin(%) | 8.25 | 10.99 | 6.46 | 16.88 | 16.63 |
| PAT Margin (%) | 6.12 | 8.29 | 4.88 | 12.60 | 12.29 |
| Cash Profit Margin (%) | 8.60 | 10.39 | 7.16 | 14.89 | 14.33 |
| Performance Ratios | |||||
| ROA(%) | 4.86 | 7.32 | 4.32 | 11.62 | 15.22 |
| ROE(%) | 7.66 | 10.96 | 6.29 | 18.19 | 28.34 |
| ROCE(%) | 9.75 | 13.78 | 8.30 | 21.40 | 30.40 |
| Asset Turnover(x) | 0.79 | 0.88 | 0.89 | 0.92 | 1.24 |
| Sales/Fixed Asset(x) | 2.21 | 2.47 | 2.53 | 2.66 | 3.30 |
| Working Capital/Sales(x) | 2.85 | 2.61 | 2.51 | 1.84 | 4.31 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.40 | 0.39 | 0.38 | 0.30 |
| Receivable days | 123.83 | 111.32 | 94.82 | 93.20 | 77.53 |
| Inventory Days | 89.24 | 79.90 | 91.76 | 94.14 | 68.65 |
| Payable days | 112.82 | 97.72 | 81.67 | 108.83 | 90.60 |
| Valuation Parameters | |||||
| PER(x) | 21.93 | 24.45 | 19.55 | 22.24 | 7.37 |
| PCE(x) | 15.61 | 19.51 | 13.33 | 18.82 | 6.32 |
| Price/Book(x) | 1.64 | 2.54 | 1.21 | 3.19 | 1.85 |
| Yield(%) | 1.71 | 1.16 | 2.72 | 1.07 | 1.43 |
| EV/Net Sales(x) | 1.54 | 2.17 | 1.08 | 2.88 | 1.04 |
| EV/Core EBITDA(x) | 12.58 | 14.95 | 10.85 | 14.03 | 5.15 |
| EV/EBIT(x) | 15.78 | 17.48 | 14.12 | 15.82 | 5.73 |
| EV/CE(x) | 1.45 | 2.25 | 1.16 | 2.25 | 1.17 |
| M Cap / Sales | 1.34 | 2.03 | 0.97 | 2.84 | 0.92 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.44 | 11.54 | 15.38 | -2.91 | 36.81 |
| Core EBITDA Growth(%) | -13.64 | 62.27 | -44.02 | -1.77 | 110.80 |
| EBIT Growth(%) | -19.50 | 80.64 | -51.50 | -2.99 | 140.82 |
| PAT Growth(%) | -24.34 | 87.11 | -55.38 | -0.93 | 193.08 |
| EPS Growth(%) | -24.46 | 87.11 | -55.38 | -11.13 | 193.07 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.29 | 0.20 | 0.17 | 0.17 | 0.27 |
| Current Ratio(x) | 1.76 | 2.08 | 2.25 | 2.74 | 1.72 |
| Quick Ratio(x) | 1.18 | 1.44 | 1.52 | 1.75 | 1.10 |
| Interest Cover(x) | 6.56 | 8.86 | 6.93 | 16.98 | 14.36 |
| Total Debt/Mcap(x) | 0.17 | 0.08 | 0.14 | 0.05 | 0.15 |
Compare Financial Ratios of peers of KOPRAN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KOPRAN | ₹808.3 Cr | -3.8% | -5.8% | -43.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹398,218.0 Cr | -0.7% | 3% | -13.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,158.0 Cr | 1.9% | 8.3% | 5.8% | Stock Analytics | |
| CIPLA | ₹126,710.0 Cr | 0.5% | 0.7% | -2.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹119,586.0 Cr | -0.1% | NA | 1.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,496.0 Cr | -2% | -5.4% | -7.5% | Stock Analytics | |
KOPRAN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KOPRAN | -3.8% |
-5.8% |
-43.5% |
| SENSEX | 1.6% |
2.1% |
2.6% |
You may also like the below Video Courses
